An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue. Investors are betting that a deeper understanding of the brain will allow BCI systems to address the significant unmet need affecting millions of people with neurological disorders. They are also chasing an opportunity where the market for BCIs could reach $400 billion – in the U.S. alone. Read More
The EMA is recommending withdrawing Amgen Inc.’s complement inhibitor Tavneos (avacopan) from the market in Europe, saying data provided at the time it assessed the MAA “were found to be incorrect and misleading and could no longer be relied upon for demonstrating Tavneos’ effectiveness.” Read More
Nature Medicine has retracted a widely publicized Chinese lung cancer study that suggested administering immunotherapy before 3 p.m. could dramatically improve survival in a decision that comes amid heightened scrutiny of research integrity and data transparency in high-impact biomedical journals. Read More
At the BIO International Convention, nonprofit and for-profit companies discussed ways to fund orphan drug development, especially for ultra-rare diseases where development costs can be challenging. One of the simplest ways to keep costs down is to skip the discovery phase and use repurposed drugs or rescue shelved therapeutic assets as the Orphan Therapeutics Accelerator has done. The Cambridge, Mass.-based accelerator was founded in 2024 to rescue shelled therapeutic assets for ultrarare diseases. Read More
Otsuka Pharmaceutical Co. Ltd. reported another clinical study win with once-daily centanafadine, a non-stimulant compound targeting attention deficit hyperactivity disorder (ADHD). Top-line results of a dedicated phase IIIb study in patients with ADHD and comorbid anxiety found that centanafadine met the primary endpoint, defined as score improvements on the Adult Investigator Symptom Rating Scale, compared with placebo at week 8. Read More
Johnson & Johnson this week launched its dual-energy Thermocool Smarttouch SF platform in Europe bringing another option to physicians looking to enhance their electrophysiology procedures. The system combines radiofrequency (RF) and pulsed field ablation in one device to treat atrial fibrillation, entering what is becoming an increasingly crowded market for cardiac ablation technology. Read More
BioWorld tracked 262 clinical trial readouts across phases I through III in May 2026, the highest monthly total so far this year and well above April’s 143, March’s 209, February’s 152 and January’s 144. By phase, BioWorld recorded 98 phase I readouts in May, 81 in phase II and 83 in phase III. Of the phase III programs, 17 trials posted positive results, and one failed to meet its primary endpoints. Read More
New hires and promotions in the biopharma and med-tech industries, including: Arrakis, Candel, Discgenics, Herantis, Insulet, Kymera, Lycia, MRM, Neogenomics. Read More
Biopharma and med-tech companies raising money in public or private financings, including: Grail, Hatch, Helus, Leyden, Lycia, Mesoblast, Optimeos, Pulsenmore, Taysha. Read More
Clinical updates for biopharma and med tech, including data readouts and publications: AL-S, Anacardio, Hutchmed, Medra, Nectero, Neurosense, Otsuka, Paragonix, Proqr, Vascarta. Read More
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Agilent, Apollomics, Arrotex, Biocare, Boehringer, Briacell, Cstone, Eledon, Eliaz, Heartbeam, Immunai, Ionis, Launxp, Natera, Novakand, Passage, Recordati, Remix, Uneedle. Read More
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Aidoc, Celecor, Cercare, Deephealth, Gilead, Ionis, Merck, Pfizer, Radnet, Reprocell, Spectral, Sunshine. Read More
